Shares of GH Research PLC (NASDAQ:GHRS - Get Free Report) shot up 0.6% during trading on Tuesday . The stock traded as high as $8.10 and last traded at $8.05. 13,641 shares were traded during trading, a decline of 83% from the average session volume of 79,417 shares. The stock had previously closed at $8.00.
Wall Street Analysts Forecast Growth
Several analysts have issued reports on the company. HC Wainwright restated a "buy" rating and set a $40.00 price objective on shares of GH Research in a research note on Thursday, September 5th. JMP Securities restated a "market outperform" rating and set a $39.00 price objective on shares of GH Research in a research note on Wednesday, September 4th.
Check Out Our Latest Stock Report on GHRS
GH Research Price Performance
The company has a market capitalization of $417.80 million, a P/E ratio of -11.97 and a beta of 0.74. The company has a fifty day moving average price of $7.96 and a 200 day moving average price of $10.50.
GH Research (NASDAQ:GHRS - Get Free Report) last released its quarterly earnings results on Tuesday, September 3rd. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.03. On average, equities research analysts predict that GH Research PLC will post -0.85 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
An institutional investor recently raised its position in GH Research stock. Lynx1 Capital Management LP grew its holdings in shares of GH Research PLC (NASDAQ:GHRS - Free Report) by 19.8% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,966,726 shares of the company's stock after purchasing an additional 656,163 shares during the period. GH Research makes up 16.7% of Lynx1 Capital Management LP's portfolio, making the stock its 3rd biggest holding. Lynx1 Capital Management LP owned 7.62% of GH Research worth $46,252,000 as of its most recent SEC filing. Institutional investors own 56.90% of the company's stock.
About GH Research
(
Get Free Report)
GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).
Featured Articles
Before you consider GH Research, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GH Research wasn't on the list.
While GH Research currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
